融资1.09亿！可穿戴神经刺激器完成A轮

Core Viewpoint - Spark Biomedical is advancing in the field of non-invasive wearable neurostimulation technology, particularly through its transcutaneous auricular neurostimulation (tAN®) method, which is gaining traction as a viable alternative to traditional drug therapies in managing chronic health issues [3][4][5]. Group 1: Company Overview - Spark Biomedical was founded in 2018 and is headquartered in Dallas, Texas, focusing on non-invasive wearable neurostimulation technology [3][13]. - The company's core technology, tAN®, delivers mild electrical pulses through the skin of the ear to stimulate the vagus and trigeminal nerves, activating the central nervous system to alleviate discomfort and maintain physiological balance [3][4]. - The representative product, Sparrow Ascent, has received FDA approval for alleviating opioid withdrawal symptoms and is applicable to both adults and newborns suffering from neonatal abstinence syndrome [5][13]. Group 2: Recent Developments - On April 30, 2025, Spark Biomedical completed a $15 million A round financing, which will be used to accelerate product development and clinical expansion in key areas such as neuro health, hemostasis, and women's health [1][8]. - The financing reflects ongoing market interest in non-drug, non-invasive neuroregulation therapies amid rising chronic disease management needs and the opioid crisis [1][8]. Group 3: Clinical Applications and Research - Spark Biomedical is expanding its clinical applications of tAN® beyond opioid withdrawal to include hemostasis, women's health, pediatric care, and chronic pain management [9][11]. - The company has established a research platform called Sparrow Link, collaborating with institutions like Battelle Memorial Institute and Hazelden Betty Ford Foundation to advance neurostimulation research [6][12]. Group 4: Technological Advancements - The company is developing an AI-driven closed-loop neurostimulation system that dynamically monitors patients' neural responses and adjusts stimulation parameters for enhanced treatment precision [10][12]. - This system aims to assist in the detection and intervention of cravings during opioid withdrawal, supported by funding from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) [10][12]. Group 5: Strategic Collaborations - Spark Biomedical has formed strategic partnerships with various organizations, including the U.S. Department of Defense, to explore the potential applications of tAN® technology in behavioral health and battlefield medicine [6][12][16]. - These collaborations provide essential support for technology validation, regulatory pathways, and market entry, enhancing the company's long-term competitiveness in the global bioelectronic therapy market [12][16].